Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

en target lesion revascularization (TLR, repeat procedures driven by lack of blood supply).

-- A 32 percent reduction in the risk of TVF compared to TAXUS (10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.

-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

"Today's approval of XIENCE V is a reflection of Abbott's ongoing commitment to bring innovation-driven, leading-edge medical technologies to the people who need them," added Capek. "With one of the largest, most seasoned vascular sales forces in the United States and with the ability to supply more than half the worldwide market, we will begin shipping units of XIENCE V immediately to meet physician demand for this much awaited, next- generation technology."

More About XIENCE V

XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V drug coated stent will be available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review for approval by Japan's Ministry of Health, Lab
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... -- Newly published research, by investigators, at ... (NESCI) in the journal STEM CELLS reported ... with "Limbal Stem Cell Deficiency" (LSCD) using ... need of suppressing their immunity. ,, ... a painful, blinding disease that requires long-term, ...
(Date:12/10/2009)... /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer and,producer of prescription drugs and licensed ... Republic of China ("PRC"), today reported that,effective ... operating entity of Lotus,appointed Mr. Jinzhong HAN ... Drug division ("OTC Division"). , ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3
... of content management systems (CMS) providers, Northwoods Software ... clients. Forget the gearhead techno-speak. The Milwaukee area firm ... through plain talk and better Web design. , ,We ... said Pat Bieser, founder and CEO of the Brown ...
... University of Wisconsin-Madison received their grades online for the first ... implemented by a team of staff members from the Universitys ... of the Registrar . , ,We worked out ... what we would release to instructors, said Connie Chatman, manager ...
... agencies have backed a new organization, the Wisconsin Angel ... , ,Wisconsin excels in researching and developing cutting-edge technology ... first and most critical stage, said Governor ... , ,The Wisconsin Technology Council , which advises ...
Other Biology Technology:Untangling the Web: Northwoods Software in profile 2Untangling the Web: Northwoods Software in profile 3Untangling the Web: Northwoods Software in profile 4Untangling the Web: Northwoods Software in profile 5UW-Madisons move to online grading goes smoothly 2
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/14/2009)... Dec. 14 MODA Technology Partners, a ... utility and product testing for the Pharmaceutical industry, ... the company,s third generation mobile data acquisition platform. ... to further automate their regulated manufacturing processes. ... ,, Fully-Configurable Test Methods: Each ...
(Date:12/13/2009)... Biologists have identified plant enzymes that may help to ... to use water more efficiently. The finding could help ... gases. , Plants take in the carbon dioxide they ... surface of leaves. But for each molecule of the ... these same openings. The pores can tighten to save ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 1The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 2The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 3The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 4Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 1Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 2Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 3Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 4The tourist trap 9540 1
... of molecular and human genetics at Baylor College of Medicine, ... bacteria stressed by starvation, sometimes resulting in a rare change ... report in the current issue of the journal Molecular Cell, ... but also show that this only occurs at a special ...
... the Public Health Agency of Canada - with assistance ... Diseases - have developed vaccines against the Ebola and ... in non-human primates. , In a study published in ... and Dr. Steven Jones of PHAC's National Microbiology Laboratory ...
... prediction. , Computers can predict the detailed structure of ... least some of the time, according to new studies ... which were reported in the September 16, 2005, issue ... that scientists eventually may be able to determine the ...
Other Biology News:Stressed cells spark DNA repair missteps and speed evolution 2Researchers report breakthrough against world’s deadliest viruses 2Computers close in on protein structure prediction 2Computers close in on protein structure prediction 3Computers close in on protein structure prediction 4
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: